Company registration number 6132656 (England and Wales)
NEW PARK PHARMACY LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2025
PAGES FOR FILING WITH REGISTRAR
NEW PARK PHARMACY LIMITED
COMPANY INFORMATION
Director
B Patel
Company number
6132656
Registered office
6 Ritherdon Road
London
SW17 8QD
Accountants
Y R Associates
6 Ritherdon Road
London
SW17 8QD
NEW PARK PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
NEW PARK PHARMACY LIMITED
BALANCE SHEET
AS AT
31 JULY 2025
31 July 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
49,890
79,890
Tangible assets
4
5,829
7,772
55,719
87,662
Current assets
Stocks
5
68,075
75,575
Debtors
6
1,294,450
1,247,971
Cash at bank and in hand
5,414
27,824
1,367,939
1,351,370
Creditors: amounts falling due within one year
7
(318,503)
(334,443)
Net current assets
1,049,436
1,016,927
Total assets less current liabilities
1,105,155
1,104,589
Creditors: amounts falling due after more than one year
8
(16,479)
(8,521)
Provisions for liabilities
(1,187)
(1,613)
Net assets
1,087,489
1,094,455
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
1,087,389
1,094,355
Total equity
1,087,489
1,094,455
NEW PARK PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 JULY 2025
31 July 2025
- 2 -

For the financial year ended 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 22 April 2026
B Patel
Director
Company registration number 6132656 (England and Wales)
NEW PARK PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2025
- 3 -
1
Accounting policies
Company information

New Park Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is 6 Ritherdon Road, London, SW17 8QD.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements have been prepared under the historical cost convention.

1.2
Revenue

Turnover represents net invoiced sales of goods and services, excluding value added tax.

1.3
Intangible fixed assets - goodwill

Goodwill, being the amount paid in connection with the acquisition of a business in 2007, is being amortised evenly over its estimated useful life of twenty years.

1.4
Tangible fixed assets

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% on reducing balance
1.5
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

1.6
Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained

Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.


Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the

timing difference.


Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

NEW PARK PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
1
Accounting policies
(Continued)
- 4 -

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
8
8
3
Intangible fixed assets
Goodwill
£
Cost
At 1 August 2024 and 31 July 2025
600,000
Amortisation and impairment
At 1 August 2024
520,110
Amortisation charged for the year
30,000
At 31 July 2025
550,110
Carrying amount
At 31 July 2025
49,890
At 31 July 2024
79,890
NEW PARK PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
- 5 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 August 2024 and 31 July 2025
136,137
Depreciation and impairment
At 1 August 2024
128,365
Depreciation charged in the year
1,943
At 31 July 2025
130,308
Carrying amount
At 31 July 2025
5,829
At 31 July 2024
7,772
5
Stocks
2025
2024
£
£
Stocks
68,075
75,575
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
138,154
116,218
Other debtors
15,901
15,207
154,055
131,425
2025
2024
Amounts falling due after more than one year:
£
£
Amounts owed by group undertakings
1,140,395
1,116,546
Total debtors
1,294,450
1,247,971
NEW PARK PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
- 6 -
7
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
8,349
11,212
Trade creditors
145,536
158,136
Corporation tax
13,735
6,523
Other taxation and social security
4,295
4,716
Other creditors
146,588
153,856
318,503
334,443
8
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
-
0
7,142
Amounts owed to group undertakings
16,479
1,379
16,479
8,521
9
Related party transactions

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

2025-07-312024-08-01falsefalsefalse22 April 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityB Patel61326562024-08-012025-07-316132656bus:Director12024-08-012025-07-316132656bus:RegisteredOffice2024-08-012025-07-3161326562025-07-3161326562024-07-316132656core:NetGoodwill2025-07-316132656core:NetGoodwill2024-07-316132656core:OtherPropertyPlantEquipment2025-07-316132656core:OtherPropertyPlantEquipment2024-07-316132656core:CurrentInventories2025-07-316132656core:CurrentInventories2024-07-316132656core:CurrentFinancialInstrumentscore:WithinOneYear2025-07-316132656core:CurrentFinancialInstrumentscore:WithinOneYear2024-07-316132656core:Non-currentFinancialInstrumentscore:AfterOneYear2025-07-316132656core:Non-currentFinancialInstrumentscore:AfterOneYear2024-07-316132656core:CurrentFinancialInstruments2025-07-316132656core:CurrentFinancialInstruments2024-07-316132656core:CurrentFinancialInstrumentscore:AfterOneYear2025-07-316132656core:CurrentFinancialInstrumentscore:AfterOneYear2024-07-316132656core:ShareCapital2025-07-316132656core:ShareCapital2024-07-316132656core:RetainedEarningsAccumulatedLosses2025-07-316132656core:RetainedEarningsAccumulatedLosses2024-07-316132656core:Goodwill2024-08-012025-07-316132656core:FurnitureFittings2024-08-012025-07-3161326562023-08-012024-07-316132656core:NetGoodwill2024-07-316132656core:NetGoodwill2024-08-012025-07-316132656core:OtherPropertyPlantEquipment2024-07-316132656core:OtherPropertyPlantEquipment2024-08-012025-07-316132656core:Non-currentFinancialInstruments2025-07-316132656core:Non-currentFinancialInstruments2024-07-316132656bus:PrivateLimitedCompanyLtd2024-08-012025-07-316132656bus:SmallCompaniesRegimeForAccounts2024-08-012025-07-316132656bus:FRS1022024-08-012025-07-316132656bus:AuditExemptWithAccountantsReport2024-08-012025-07-316132656bus:FullAccounts2024-08-012025-07-31xbrli:purexbrli:sharesiso4217:GBP